It was noteworthy that pancreatitis ranked 7th among the top 10 gastrointestinal AEs in terms of the number of reports, showing strong signal strength with ROR 20.27 (18.2922.47) in the current study (Figure 2)
SURMOUNT-5 head-to-head data The SURMOUNT-5 trial, published in the New England Journal of Medicine, was the first large-scale head-to-head comparison of tirzepatide and semaglutide
Ozempic creates a compounding delay that frequently triggers the worst side effects
Achieving and maintaining long-term glycemic control is often challenging, and many current agents have treatment-limiting side effects [28]
The medication slows gastric emptying significantly, which can worsen conditions like gastroparesis, severe GERD, or inflammatory bowel disease
Important clinical considerations include: The metabolic changes generally track with body weight